Qvr LLC Has $869,000 Holdings in AbbVie Inc. $ABBV

Qvr LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 42.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,805 shares of the company’s stock after selling 2,825 shares during the quarter. AbbVie makes up about 0.0% of Qvr LLC’s investment portfolio, making the stock its 20th largest position. Qvr LLC’s holdings in AbbVie were worth $869,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ABBV. Brighton Jones LLC grew its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. boosted its position in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC boosted its position in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after acquiring an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its position in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after acquiring an additional 612,702 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.6%

NYSE:ABBV opened at $204.95 on Wednesday. The firm has a market cap of $362.38 billion, a PE ratio of 86.84, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 12 month low of $170.91 and a 12 month high of $244.81. The company’s 50-day moving average price is $218.27 and its two-hundred day moving average price is $222.93.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts expect that AbbVie Inc. will post 14.26 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie’s payout ratio is currently 293.22%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several recent research reports. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price on the stock. Canaccord Genuity Group initiated coverage on shares of AbbVie in a research report on Monday. They set a “buy” rating and a $262.00 target price on the stock. Citigroup decreased their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Finally, Evercore decreased their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord initiated coverage with a Buy and $262 price target, calling AbbVie a “core holding” and highlighting a “solid and visible” growth profile built on three franchise pillars — the note reinforces a sizable upside vs. current levels and may boost investor demand. Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?
• Positive Sentiment: RBC (and other Street bulls) continue to view ABBV as a top large-cap buy; RBC’s maintained Buy and ~$260 target keeps analyst sentiment constructive and supports multiple buy-side narratives. AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street
• Positive Sentiment: AbbVie hit a third milestone under its neurology collaboration (Nxera), triggering a ~$10M payment — a concrete, near-term validation of deal progress and a reminder that partnership milestones could add non-dilutive value and future upside. Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
• Positive Sentiment: Retail/independent bullish pieces continue to buy the dip, framing AbbVie’s dividend, pipeline and buybacks as durable supports — this persistent investor interest can amplify rebounds on positive catalysts. Why I Can’t Stop Buying AbbVie Stock
• Neutral Sentiment: AbbVie is sponsoring a new BioLabs facility in Toronto — a strategic R&D/innovation move that supports ecosystem development but has limited near-term revenue impact. AbbVie Sponsors New BioLabs Facility in Toronto
• Neutral Sentiment: AbbVie launched a cross‑agency psoriasis marketing campaign (“PSO Done”) — helpful for brand awareness and adoption but unlikely to move near-term top-line materially on its own. AbbVie launches ‘PSO Done’ psoriasis campaign with a cross-agency effort
• Negative Sentiment: Zacks warns AbbVie’s oncology franchise faces pressure — Imbruvica declines and pricing headwinds may weigh on Q1 top-line growth, a near-term risk to revenue expectations and investor sentiment. Will AbbVie’s Oncology Franchise Weigh on Q1 Top-line Growth?
• Negative Sentiment: Recent coverage noted ABBV shares pulled back and underperformed the broader market in the latest session — a sign of profit taking and sensitivity to near-term growth concerns that could amplify downside absent fresh positive catalysts. Here’s Why AbbVie (ABBV) Fell More Than Broader Market

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.